{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/34580"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/34580","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Small molecule inhibitors of steroid receptors for breast and prostate cancer","abstract":"Steroid hormone receptors play a critical role in the growth and progression of hormone-dependent cancers. This thesis aimed at identifying and characterizing new chemical entities with therapeutic potential in breast and prostate cancer treatment. Reported here are two inhibitors that antagonize androgen receptor (AR) function and one that suppresses estrogen receptor (ER) signaling. Moderate-to-high throughput screens of chemical libraries were designed and implemented to identify these inhibitors. The most promising inhibitor of AR transactivation to have emerged from the rigorous screening process was CPIC (1-(3-(2-chlorophenoxy) propyl)-1H-indole-3-carbonitrile). CPIC is capable of potently and specifically reducing androgen-induced proliferation and gene expression in prostate cancer cells. CPIC also inhibited recruitment of androgen-bound AR to the DNA regulatory sites of target genes in multiple cell lines. CPIC exhibits a mode of action different from that of classical AR antagonists, bicalutamide or flutamide. Additionally, CPIC at nanomolar concentrations, but not bicalutamide, disrupts the amino-carboxyl (N/C) terminal interaction of AR, which is crucial for optimum androgen-mediated AR signaling. Also described here is a novel non-competitive inhibitor of AR action, AR54 (2-(pyrimidin-2-ylthio)-1-(2,2,4-trimethyl-4-phenyl-3,4-dihydroquinolin-1(2H)-yl)ethanone). AR54 blocks prostate cancer cell proliferation by reducing AR mRNA levels and down-regulating AR protein levels. We have not yet determined whether AR54 reduces the production of AR transcripts or increases the rate of mRNA degradation. AR54 modestly inhibits both androgen-dependent and androgen-independent proliferation of 22Rv1 cells, a model for castration-recurrent prostate cancer. These novel small molecule inhibitors represent important new probes for understanding AR action. In addition, CPIC and its structural analogues have properties that make them suitable for further evaluation and development as therapeutics for aggressive late-stage prostate cancers resistant to current therapies.","abstract_html":"Steroid hormone receptors play a critical role in the growth and progression of hormone-dependent cancers. This thesis aimed at identifying and characterizing new chemical entities with therapeutic potential in breast and prostate cancer treatment. Reported here are two inhibitors that antagonize androgen receptor (AR) function and one that suppresses estrogen receptor (ER) signaling. Moderate-to-high throughput screens of chemical libraries were designed and implemented to identify these inhibitors. The most promising inhibitor of AR transactivation to have emerged from the rigorous screening process was CPIC (1-(3-(2-chlorophenoxy) propyl)-1H-indole-3-carbonitrile). CPIC is capable of potently and specifically reducing androgen-induced proliferation and gene expression in prostate cancer cells. CPIC also inhibited recruitment of androgen-bound AR to the DNA regulatory sites of target genes in multiple cell lines. CPIC exhibits a mode of action different from that of classical AR antagonists, bicalutamide or flutamide. Additionally, CPIC at nanomolar concentrations, but not bicalutamide, disrupts the amino-carboxyl (N/C) terminal interaction of AR, which is crucial for optimum androgen-mediated AR signaling. Also described here is a novel non-competitive inhibitor of AR action, AR54 (2-(pyrimidin-2-ylthio)-1-(2,2,4-trimethyl-4-phenyl-3,4-dihydroquinolin-1(2H)-yl)ethanone). AR54 blocks prostate cancer cell proliferation by reducing AR mRNA levels and down-regulating AR protein levels. We have not yet determined whether AR54 reduces the production of AR transcripts or increases the rate of mRNA degradation. AR54 modestly inhibits both androgen-dependent and androgen-independent proliferation of 22Rv1 cells, a model for castration-recurrent prostate cancer. These novel small molecule inhibitors represent important new probes for understanding AR action. In addition, CPIC and its structural analogues have properties that make them suitable for further evaluation and development as therapeutics for aggressive late-stage prostate cancers resistant to current therapies.","abstract_has_math":false,"creators":["Cherian, Milu"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Molecular & Integrative Physi","degree_department":null,"school":null,"contributors":["Shapiro, David J.","Katzenellenbogen, Benita S.","Hergenrother, Paul J.","Bolton, Eric C."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2012,"date_issued":"2012-09-18T21:26:30Z","date_published":"2012-09-18T21:26:30Z","updated_at":"2026-07-22T22:25:31Z","subjects":["Androgen receptor","Prostate cancer","1-(3-(2-chlorophenoxy)propyl)-1H-indole-3-carbonitrile (CPIC)","Drug discovery","Small molecule","High throughput screening"],"languages":["en"],"rights":["Copyright 2012 Milu Cherian"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/34580","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Shapiro, David J.","Katzenellenbogen, Benita S.","Hergenrother, Paul J.","Bolton, Eric C."]},{"key":"dc:creator","label":"Author","values":["Cherian, Milu"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2012-09-18T21:26:30Z","2014-09-18T10:00:47Z","2012-08"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Molecular & Integrative Physi"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Androgen receptor","Prostate cancer","1-(3-(2-chlorophenoxy)propyl)-1H-indole-3-carbonitrile (CPIC)","Drug discovery","Small molecule","High throughput screening"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2012 Milu Cherian"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/34580"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Steroid hormone receptors play a critical role in the growth and progression of hormone-dependent cancers. This thesis aimed at identifying and characterizing new chemical entities with therapeutic potential in breast and prostate cancer treatment. Reported here are two inhibitors that antagonize androgen receptor (AR) function and one that suppresses estrogen receptor (ER) signaling. Moderate-to-high throughput screens of chemical libraries were designed and implemented to identify these inhibitors. The most promising inhibitor of AR transactivation to have emerged from the rigorous screening process was CPIC (1-(3-(2-chlorophenoxy) propyl)-1H-indole-3-carbonitrile). CPIC is capable of potently and specifically reducing androgen-induced proliferation and gene expression in prostate cancer cells. CPIC also inhibited recruitment of androgen-bound AR to the DNA regulatory sites of target genes in multiple cell lines. CPIC exhibits a mode of action different from that of classical AR antagonists, bicalutamide or flutamide. Additionally, CPIC at nanomolar concentrations, but not bicalutamide, disrupts the amino-carboxyl (N/C) terminal interaction of AR, which is crucial for optimum androgen-mediated AR signaling. Also described here is a novel non-competitive inhibitor of AR action, AR54 (2-(pyrimidin-2-ylthio)-1-(2,2,4-trimethyl-4-phenyl-3,4-dihydroquinolin-1(2H)-yl)ethanone). AR54 blocks prostate cancer cell proliferation by reducing AR mRNA levels and down-regulating AR protein levels. We have not yet determined whether AR54 reduces the production of AR transcripts or increases the rate of mRNA degradation. AR54 modestly inhibits both androgen-dependent and androgen-independent proliferation of 22Rv1 cells, a model for castration-recurrent prostate cancer. These novel small molecule inhibitors represent important new probes for understanding AR action. In addition, CPIC and its structural analogues have properties that make them suitable for further evaluation and development as therapeutics for aggressive late-stage prostate cancers resistant to current therapies.","Item withdrawn by Mark Zulauf (zulauf@illinois.edu) on 2012-07-07T16:20:39Z Item was in collections: University of Illinois Theses & Dissertations (ID: 1) No. of bitstreams: 1 Cherian_Milu.pdf: 30040401 bytes, checksum: edb07562aa82b53aee1d651c8e67721a (MD5)","Made available in DSpace on 2012-09-18T21:26:30Z (GMT). No. of bitstreams: 2 Cherian_Milu.pdf: 30040401 bytes, checksum: edb07562aa82b53aee1d651c8e67721a (MD5) license.txt: 4062 bytes, checksum: 74580635e5854da5b666d057ccf43f61 (MD5)","Item marked as restricted to the 'Administrator' Group (id=1) by Seth Robbins (srobbins@illinois.edu) on 2012-09-18T21:27:35Z Item is restricted until 2014-09-18T21:27:16Z","Restriction data tranferred 2014-07-01T11:35:54-05:00 Original Data Group with Access Administrator Release Date: 2014-09-18 16:27:16 UTC Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 34854 on 2014-09-18T10:00:47Z."]},{"key":"dc:title","label":"Title","values":["Small molecule inhibitors of steroid receptors for breast and prostate cancer"]}]}],"canonical_facts":{"dc:contributor":["Shapiro, David J.","Katzenellenbogen, Benita S.","Hergenrother, Paul J.","Bolton, Eric C."],"dc:creator":["Cherian, Milu"],"dc:date":["2012-09-18T21:26:30Z","2014-09-18T10:00:47Z","2012-08"],"dc:description":["Steroid hormone receptors play a critical role in the growth and progression of hormone-dependent cancers. This thesis aimed at identifying and characterizing new chemical entities with therapeutic potential in breast and prostate cancer treatment. Reported here are two inhibitors that antagonize androgen receptor (AR) function and one that suppresses estrogen receptor (ER) signaling. Moderate-to-high throughput screens of chemical libraries were designed and implemented to identify these inhibitors. The most promising inhibitor of AR transactivation to have emerged from the rigorous screening process was CPIC (1-(3-(2-chlorophenoxy) propyl)-1H-indole-3-carbonitrile). CPIC is capable of potently and specifically reducing androgen-induced proliferation and gene expression in prostate cancer cells. CPIC also inhibited recruitment of androgen-bound AR to the DNA regulatory sites of target genes in multiple cell lines. CPIC exhibits a mode of action different from that of classical AR antagonists, bicalutamide or flutamide. Additionally, CPIC at nanomolar concentrations, but not bicalutamide, disrupts the amino-carboxyl (N/C) terminal interaction of AR, which is crucial for optimum androgen-mediated AR signaling. Also described here is a novel non-competitive inhibitor of AR action, AR54 (2-(pyrimidin-2-ylthio)-1-(2,2,4-trimethyl-4-phenyl-3,4-dihydroquinolin-1(2H)-yl)ethanone). AR54 blocks prostate cancer cell proliferation by reducing AR mRNA levels and down-regulating AR protein levels. We have not yet determined whether AR54 reduces the production of AR transcripts or increases the rate of mRNA degradation. AR54 modestly inhibits both androgen-dependent and androgen-independent proliferation of 22Rv1 cells, a model for castration-recurrent prostate cancer. These novel small molecule inhibitors represent important new probes for understanding AR action. In addition, CPIC and its structural analogues have properties that make them suitable for further evaluation and development as therapeutics for aggressive late-stage prostate cancers resistant to current therapies.","Item withdrawn by Mark Zulauf (zulauf@illinois.edu) on 2012-07-07T16:20:39Z Item was in collections: University of Illinois Theses & Dissertations (ID: 1) No. of bitstreams: 1 Cherian_Milu.pdf: 30040401 bytes, checksum: edb07562aa82b53aee1d651c8e67721a (MD5)","Made available in DSpace on 2012-09-18T21:26:30Z (GMT). No. of bitstreams: 2 Cherian_Milu.pdf: 30040401 bytes, checksum: edb07562aa82b53aee1d651c8e67721a (MD5) license.txt: 4062 bytes, checksum: 74580635e5854da5b666d057ccf43f61 (MD5)","Item marked as restricted to the 'Administrator' Group (id=1) by Seth Robbins (srobbins@illinois.edu) on 2012-09-18T21:27:35Z Item is restricted until 2014-09-18T21:27:16Z","Restriction data tranferred 2014-07-01T11:35:54-05:00 Original Data Group with Access Administrator Release Date: 2014-09-18 16:27:16 UTC Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 34854 on 2014-09-18T10:00:47Z."],"dc:identifier":["http://hdl.handle.net/2142/34580"],"dc:language":["en"],"dc:rights":["Copyright 2012 Milu Cherian"],"dc:subject":["Androgen receptor","Prostate cancer","1-(3-(2-chlorophenoxy)propyl)-1H-indole-3-carbonitrile (CPIC)","Drug discovery","Small molecule","High throughput screening"],"dc:title":["Small molecule inhibitors of steroid receptors for breast and prostate cancer"],"thesis:degree_discipline":["Molecular & Integrative Physi"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:25:31Z"}